68 related articles for article (PubMed ID: 38553708)
21. Immunosuppression by Inflammation-Stimulated Amplification of Myeloid-Derived Suppressor Cells and Changes in Expression of Immune Checkpoint HHLA2 in Chronic Obstructive Pulmonary Disease.
Xu L; Li F; Jiang M; Li Z; Xu D; Jing J; Wang J; Ding J
Int J Chron Obstruct Pulmon Dis; 2023; 18():139-153. PubMed ID: 36846109
[TBL] [Abstract][Full Text] [Related]
22. Intratumoral CD8
Virassamy B; Caramia F; Savas P; Sant S; Wang J; Christo SN; Byrne A; Clarke K; Brown E; Teo ZL; von Scheidt B; Freestone D; Gandolfo LC; Weber K; Teply-Szymanski J; Li R; Luen SJ; Denkert C; Loibl S; Lucas O; Swanton C; Speed TP; Darcy PK; Neeson PJ; Mackay LK; Loi S
Cancer Cell; 2023 Mar; 41(3):585-601.e8. PubMed ID: 36827978
[TBL] [Abstract][Full Text] [Related]
23. KIR3DL3-HHLA2 and TMIGD2-HHLA2 pathways: The dual role of HHLA2 in immune responses and its potential therapeutic approach for cancer immunotherapy.
Li Y; Lv C; Yu Y; Wu B; Zhang Y; Lang Q; Liang Z; Zhong C; Shi Y; Han S; Xu F; Tian Y
J Adv Res; 2023 May; 47():137-150. PubMed ID: 35933091
[TBL] [Abstract][Full Text] [Related]
24. Molecular and Clinicopathological Characteristics of Lung Cancer Concomitant Chronic Obstructive Pulmonary Disease (COPD).
Ma H; Zhang Q; Zhao Y; Zhang Y; Zhang J; Chen G; Tan Y; Zhang Q; Duan Q; Sun T; Qi C; Li F
Int J Chron Obstruct Pulmon Dis; 2022; 17():1601-1612. PubMed ID: 35860812
[TBL] [Abstract][Full Text] [Related]
25. Tissue-Resident Memory T Cells Underlie Neoadjuvant Immunotherapy Response.
Cancer Discov; 2022 Sep; 12(9):OF2. PubMed ID: 35838402
[TBL] [Abstract][Full Text] [Related]
26. Tissue-resident memory and circulating T cells are early responders to pre-surgical cancer immunotherapy.
Luoma AM; Suo S; Wang Y; Gunasti L; Porter CBM; Nabilsi N; Tadros J; Ferretti AP; Liao S; Gurer C; Chen YH; Criscitiello S; Ricker CA; Dionne D; Rozenblatt-Rosen O; Uppaluri R; Haddad RI; Ashenberg O; Regev A; Van Allen EM; MacBeath G; Schoenfeld JD; Wucherpfennig KW
Cell; 2022 Aug; 185(16):2918-2935.e29. PubMed ID: 35803260
[TBL] [Abstract][Full Text] [Related]
27. Quantitative evaluation of emphysema for predicting immunotherapy response in patients with advanced non-small-cell lung cancer.
Noda Y; Shiroyama T; Masuhiro K; Amiya S; Enomoto T; Adachi Y; Hara R; Niitsu T; Naito Y; Miyake K; Koyama S; Hirata H; Nagatomo I; Takeda Y; Kumanogoh A
Sci Rep; 2022 May; 12(1):8881. PubMed ID: 35614345
[TBL] [Abstract][Full Text] [Related]
28. Tissue-resident memory T cells in gastrointestinal cancer immunology and immunotherapy: ready for prime time?
Abdeljaoued S; Arfa S; Kroemer M; Ben Khelil M; Vienot A; Heyd B; Loyon R; Doussot A; Borg C
J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35470231
[TBL] [Abstract][Full Text] [Related]
29. Coexpression of HHLA2 and PD-L1 on Tumor Cells Independently Predicts the Survival of Spinal Chordoma Patients.
Xia C; Huang W; Chen YL; Fu HB; Tang M; Zhang TL; Li J; Lv GH; Yan YG; Ouyang ZH; Yao N; Wang C; Zou MX
Front Immunol; 2021; 12():797407. PubMed ID: 35145510
[TBL] [Abstract][Full Text] [Related]
30. Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers.
Caushi JX; Zhang J; Ji Z; Vaghasia A; Zhang B; Hsiue EH; Mog BJ; Hou W; Justesen S; Blosser R; Tam A; Anagnostou V; Cottrell TR; Guo H; Chan HY; Singh D; Thapa S; Dykema AG; Burman P; Choudhury B; Aparicio L; Cheung LS; Lanis M; Belcaid Z; El Asmar M; Illei PB; Wang R; Meyers J; Schuebel K; Gupta A; Skaist A; Wheelan S; Naidoo J; Marrone KA; Brock M; Ha J; Bush EL; Park BJ; Bott M; Jones DR; Reuss JE; Velculescu VE; Chaft JE; Kinzler KW; Zhou S; Vogelstein B; Taube JM; Hellmann MD; Brahmer JR; Merghoub T; Forde PM; Yegnasubramanian S; Ji H; Pardoll DM; Smith KN
Nature; 2021 Aug; 596(7870):126-132. PubMed ID: 34290408
[TBL] [Abstract][Full Text] [Related]
31. KIR3DL3-HHLA2 is a human immunosuppressive pathway and a therapeutic target.
Wei Y; Ren X; Galbo PM; Moerdler S; Wang H; Sica RA; Etemad-Gilbertson B; Shi L; Zhu L; Tang X; Lin Q; Peng M; Guan F; Zheng D; Chinai JM; Zang X
Sci Immunol; 2021 Jul; 6(61):. PubMed ID: 34244312
[TBL] [Abstract][Full Text] [Related]
32. Smoking and Human Immunodeficiency Virus 1 Infection Promote Retention of CD8
Corleis B; Cho JL; Gates SJ; Linder AH; Dickey A; Lisanti-Park AC; Schiff AE; Ghebremichael M; Kohli P; Winkler T; Harris RS; Medoff BD; Kwon DS
Am J Respir Cell Mol Biol; 2021 Nov; 65(5):513-520. PubMed ID: 34166603
[TBL] [Abstract][Full Text] [Related]
33. Impact of chronic obstructive pulmonary disease on immune checkpoint inhibitor efficacy in advanced lung cancer and the potential prognostic factors.
Zhou J; Chao Y; Yao D; Ding N; Li J; Gao L; Zhang Y; Xu X; Zhou J; Halmos B; Tsoukalas N; Kataoka Y; de Mello RA; Song Y; Hu J
Transl Lung Cancer Res; 2021 May; 10(5):2148-2162. PubMed ID: 34164266
[TBL] [Abstract][Full Text] [Related]
34. Intratumoral CD103+ CD8+ T cells predict response to PD-L1 blockade.
Banchereau R; Chitre AS; Scherl A; Wu TD; Patil NS; de Almeida P; Kadel Iii EE; Madireddi S; Au-Yeung A; Takahashi C; Chen YJ; Modrusan Z; McBride J; Nersesian R; El-Gabry EA; Robida MD; Hung JC; Kowanetz M; Zou W; McCleland M; Caplazi P; Eshgi ST; Koeppen H; Hegde PS; Mellman I; Mathews WR; Powles T; Mariathasan S; Grogan J; O'Gorman WE
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33827905
[TBL] [Abstract][Full Text] [Related]
35. Tissue-resident memory T cells in tumor immunity and immunotherapy.
Okła K; Farber DL; Zou W
J Exp Med; 2021 Apr; 218(4):. PubMed ID: 33755718
[TBL] [Abstract][Full Text] [Related]
36. Coexistence of Emphysema With Non-small-cell Lung Cancer Predicts the Therapeutic Efficacy of Immune Checkpoint Inhibitors.
Takayama Y; Nakamura T; Fukushiro Y; Mishima S; Masuda K; Shoda H
In Vivo; 2021; 35(1):467-474. PubMed ID: 33402498
[TBL] [Abstract][Full Text] [Related]
37. CD103
Corgnac S; Malenica I; Mezquita L; Auclin E; Voilin E; Kacher J; Halse H; Grynszpan L; Signolle N; Dayris T; Leclerc M; Droin N; de Montpréville V; Mercier O; Validire P; Scoazec JY; Massard C; Chouaib S; Planchard D; Adam J; Besse B; Mami-Chouaib F
Cell Rep Med; 2020 Oct; 1(7):100127. PubMed ID: 33205076
[TBL] [Abstract][Full Text] [Related]
38. The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee.
Sholl LM; Hirsch FR; Hwang D; Botling J; Lopez-Rios F; Bubendorf L; Mino-Kenudson M; Roden AC; Beasley MB; Borczuk A; Brambilla E; Chen G; Chou TY; Chung JH; Cooper WA; Dacic S; Lantuejoul S; Jain D; Lin D; Minami Y; Moreira A; Nicholson AG; Noguchi M; Papotti M; Pelosi G; Poleri C; Rekhtman N; Tsao MS; Thunnissen E; Travis W; Yatabe Y; Yoshida A; Daigneault JB; Zehir A; Peters S; Wistuba II; Kerr KM; Longshore JW
J Thorac Oncol; 2020 Sep; 15(9):1409-1424. PubMed ID: 32522712
[TBL] [Abstract][Full Text] [Related]
39. B7-H7 (HHLA2) inhibits T-cell activation and proliferation in the presence of TCR and CD28 signaling.
Rieder SA; Wang J; White N; Qadri A; Menard C; Stephens G; Karnell JL; Rudd CE; Kolbeck R
Cell Mol Immunol; 2021 Jun; 18(6):1503-1511. PubMed ID: 32005952
[TBL] [Abstract][Full Text] [Related]
40. HHLA2 and PD-L1 co-expression predicts poor prognosis in patients with clear cell renal cell carcinoma.
Zhou QH; Li KW; Chen X; He HX; Peng SM; Peng SR; Wang Q; Li ZA; Tao YR; Cai WL; Liu RY; Huang H
J Immunother Cancer; 2020 Jan; 8(1):. PubMed ID: 31959726
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
